Research programme: lysosomal storage disease therapeutics - ArmaGen Technologies

Drug Profile

Research programme: lysosomal storage disease therapeutics - ArmaGen Technologies

Alternative Names: AGT-183; AGT-184; HIRMAb-ASA fusion protein - ArmaGen Technologies; IgG-ASA fusion protein - ArmaGen Technologies; Recombinant N-sulphoglucosamine sulphohydrolase - ArmaGen Technologies; Recombinant sulfamidase - ArmaGen Technologies

Latest Information Update: 04 Jul 2016

Price : $50

At a glance

  • Originator ArmaGen Technologies
  • Developer ArmaGen Technologies; Department of Veterans Affairs; Saint Louis University; University of California at Los Angeles; University of Texas Medical Branch
  • Class Arylsulfatases; Enzymes; Immunoglobulin fusion proteins; Monoclonal antibodies
  • Mechanism of Action Arylsulfatase replacements; Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Metachromatic leukodystrophy; Mucopolysaccharidosis III

Most Recent Events

  • 04 Jul 2016 Preclinical development is ongoing for Mucopolysaccharidosis III and Metachromatic leukodystrophy in USA (ArmaGen Technologies pipeline, July 2016)
  • 25 Dec 2012 Preclinical trials in Metachromatic leukodystrophy in USA (IV) before December 2012
  • 29 Apr 2008 Preclinical trials in Mucopolysaccharidosis III in USA (IV) before April 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top